Viagra
Product Images NDC 54868-4084

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Viagra (NDC 54868-4084). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

Viagra 50 mg tablet blister packaging label from Physicians Total Care, Inc. The label includes the drug name, active ingredient sildenafil citrate, strength (50 mg), and package size (5 tablets). It lists storage instructions, usage caution, and identifies the lot number and expiration date.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Viagra 100 mg tablet container label from Physicians Total Care, Inc. The label indicates it contains 15 tablets of sildenafil citrate, each 100 mg. Includes warnings about prescription dispensing, storage instructions at controlled room temperature, and safety precautions to keep out of reach of children. Also shows lot number, NDC 54868-4786-6 and reordering information.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

Viagra 25 mg tablets packaging label from Physicians Total Care, Inc. The label shows the product name, active ingredient sildenafil citrate, strength of 25 mg, package containing 4 tablets, and includes barcode and lot/expiration details. Warning about federal law restricting dispensing without prescription is also visible.*

FDA Label Image

Chemical Structure (Viagra 01)

Chemical structure of the active ingredient in Viagra as shown in the image. The diagram illustrates the molecular formula with various chemical groups bonded, including a purine core, methyl, ethyl groups, and a sulfonamide group.*

FDA Label Image

Figure 1 (Viagra 02)

A line graph comparing systolic blood pressure (mmHg) over time (hours) post dose between Sildenafil 100mg and placebo groups. The x-axis represents time from pre-dose up to 24 hours, and the y-axis shows changes in systolic blood pressure, with two distinct lines depicting trends for each treatment.*

FDA Label Image

Figure 2 (Viagra 03)

A line graph comparing the change in SBP (mmHg) over a time postdose interval of 0 to 8 hours. The graph shows two data series: Doxazosin with Placebo (blue line) and Doxazosin with Sildenafil 25 mg (black line), illustrating how SBP changes vary over time with these treatments.*

FDA Label Image

Figure 3 (Viagra 04)

A line graph comparing the change in serum creatinine over time postdose (hours) for two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 50 mg. The Y-axis represents change in serum creatinine, and the X-axis shows time in hours after administration.*

FDA Label Image

Figure 4 (Viagra 05)

A line graph comparing the effect of Doxazosin plus Sildenafil 100 mg versus Doxazosin plus Placebo over time after dosing (hours). The y-axis shows mmHg values, indicating change, over an 8-hour period on the x-axis. Two lines represent the treatment groups, depicting variations over time.*

FDA Label Image

Figure 5 (Viagra 06)

A pharmacokinetic curve showing plasma concentration (ng/mL) versus time post dose (hours) for a commercial tablet treatment. The graph depicts a peak concentration occurring shortly after dosing, followed by a gradual decline over 24 hours.*

FDA Label Image

Figure 6 (Viagra 07)

A bar chart titled 'Effect of VIAGRA on Maintenance of Erection by Baseline Score' showing percentages of patients at endpoint on the y-axis and baseline score on the x-axis from 0 to 5. The chart includes multiple bars per baseline score, differentiated by a legend with categories labeled 0 to 5, illustrating the distribution of patient outcomes by baseline score.*

FDA Label Image

Figure 6 (Viagra 08)

A bar graph titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint across baseline scores 0 to 5. Different bars represent scores from 0 to 5, illustrating varying patient response rates for each baseline score.*

FDA Label Image

Figure 7 (Viagra 09)

A bar graph comparing the percentage of patients reporting improvement across four treatment groups: Placebo, Viagra 25 mg, Viagra 50 mg, and Viagra 100 mg. The graph shows increasing improvement percentages from placebo up to the highest dose of Viagra.*

FDA Label Image

Logo (Viagra 10)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.